Skip to main content
. 2017 Nov 7;10(1):166–176. doi: 10.1080/19420862.2017.1387346

Figure 2.

Figure 2.

(A) Stacked HIC profiles for single batches of Yisaipu, Etanar®, Etacept, and Qiangke versus Enbrel® RS. (Similarly atypical profiles were obtained for all batches of each product and are not comparable to Enbrel® RS). (B) Stacked SE-HPLC profiles for single batches of Yisaipu, Etanar®, Etacept, and Qiangke versus Enbrel® RS. (Higher levels of aggregate were observed in all batches of each IC). (C) Stacked N-linked oligosaccharide HPLC profiles for Altebrel™, Infinitam, Intacept, and Qiangke versus Enbrel® RS. (Atypical profiles with new N-glycan species observed). (D) Stacked anion exchange HPLC profiles for overall negative charge heterogeneity of Yisaipu, Etanar®, Etacept, Altebrel™, Qiangke, and Intacept. (Shift in overall charge profiles versus Enbrel® RS). AU, absorbance units; HIC, hydrophobic interaction chromatography; HPLC, high-performance liquid chromatography; IC, intended copy; RS, reference standard; SE, size-exclusion.